Literature DB >> 12143330

The treatment of acute bronchitis by general practitioners in the UK. Results of a cross sectional postal survey.

Nigel P Stocks1, Tom Fahey.   

Abstract

BACKGROUND: In Australia and the UK acute bronchitis is a common presenting problem in general practice. When symptoms persist management can be difficult and despite evidence that antibiotics are usually ineffective their use is widespread.
OBJECTIVE: To describe prescribing behaviour for acute bronchitis by general practitioners in the United Kingdom.
METHOD: Cross sectional postal survey of UK GPs.
RESULTS: Four hundred and nineteen (73%) GPs responded. Purulent sputum, fever and crepitations/crackles on chest examination were the most important reasons for prescribing antibiotics: 89% of GPs said the colour of the sputum influenced their decision; amoxycillin was the first choice; 40% of GPs believed that at least one in five consultations for ARI were affected by patient factors, usually to maintain patient satisfaction. 47% of GPs advised the use of bronchodilators, and 96% recommended the symptomatic use of paracetamol and fluids.
CONCLUSION: General practitioners are influenced to use antibiotics by patient symptoms and signs for which there is little evidence. Patient psychosocial factors influence prescribing. Until clearer research findings from new studies are available, GPs may opt for a 'just in case' prescription.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12143330

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  3 in total

1.  Acute cough in adults.

Authors:  Graham Worrall
Journal:  Can Fam Physician       Date:  2011-01       Impact factor: 3.275

2.  One hundred coughs: family practice case series.

Authors:  Graham J Worrall
Journal:  Can Fam Physician       Date:  2008-02       Impact factor: 3.275

Review 3.  Context and general practitioner decision-making - a scoping review of contextual influence on antibiotic prescribing.

Authors:  Resha Al-Azzawi; Peder A Halvorsen; Torsten Risør
Journal:  BMC Fam Pract       Date:  2021-11-15       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.